3MC Syndrome — Comprehensive Disease Characterization Report

Prepared for a disease knowledge base entry. Evidence type is human clinical unless otherwise noted (model organism / in vitro / computational). Primary literature cited by PMID.

Summary (Answer to the Research Question)

3MC syndrome is a rare, autosomal-recessive congenital malformation syndrome that unifies four historically separate disorders — Malpuech, Michels, Mingarelli and Carnevale syndromes ("3MC"). It is caused by biallelic loss-of-function variants in one of three genes of the lectin pathway of complement: MASP1 (encoding MASP-1/MASP-3), COLEC11 (encoding collectin-11/CL-K1), and COLEC10 (encoding collectin-10/CL-L1). The shared mechanism is loss of a collectin/MASP-3 chemoattractant guidance cue required for neural crest cell migration, producing a distinctive facial gestalt (hypertelorism, blepharophimosis, blepharoptosis, highly arched eyebrows) together with cleft lip/palate, postnatal growth deficiency, developmental delay, hearing loss, a characteristic caudal appendage, skeletal (craniosynostosis, radioulnar synostosis) and genitourinary anomalies (PMIDs 21258343, 28301481).

1. Disease Information

• Overview: A rare autosomal-recessive multiple-congenital-anomaly / dysmorphism syndrome affecting craniofacial, skeletal, genitourinary, ophthalmic and (variably) cardiac development. The name "3MC" was proposed as a unifying term for the overlapping Carnevale, Mingarelli, Malpuech and Michels syndromes (21258343).
• Key identifiers (suggested):
• MONDO: MONDO:0018721 ("3MC syndrome") — with subtypes 3MC syndrome type 1/2/3.
• OMIM (phenotype): 3MC syndrome 1 (#257920, MASP1/COLEC11 — historically Malpuech/Carnevale), 3MC syndrome 2 (#265050, COLEC11), 3MC syndrome 3 (#248340, COLEC10 — historically Michels). (PMIDs 36503917, 34636477)
• OMIM (gene): MASP1 600521; COLEC11 612502; COLEC10 *607620.
• Orphanet: ORPHA:293843 (3MC syndrome); legacy entries Malpuech syndrome (ORPHA:1993), Michels syndrome (ORPHA:1394), Carnevale/Mingarelli.
• ICD-10: Q87.0 (congenital malformation syndromes predominantly affecting facial appearance). ICD-11: LD2F.0Y (other specified syndromes with facial features as a major feature).
• MeSH: No dedicated descriptor; indexed under "Abnormalities, Multiple" / supplementary concept "3MC syndrome."
• Synonyms / alternative names: Malpuech–Michels–Mingarelli–Carnevale syndrome; Malpuech facial clefting syndrome; Michels syndrome; Carnevale syndrome; Mingarelli syndrome; Malpuech syndrome; OSA syndrome; craniofacial-ulnar-renal syndrome; blepharophimosis-ptosis-cleft-lip syndrome (descriptive).
• Data derivation: Information here is derived from aggregated disease-level resources (OMIM/Orphanet) and individual patient case reports / small cohorts (fewer than ~100 molecularly confirmed patients worldwide). There is no large EHR-based dataset for this ultra-rare disorder.

2. Etiology

• Primary cause — genetic: Biallelic (homozygous or compound heterozygous) pathogenic variants in MASP1, COLEC11, or COLEC10 — all encoding components of the lectin complement pathway (21258343: "identified two mutated genes, COLEC11 and MASP1, both of which encode proteins in the lectin complement pathway"; 28301481 for COLEC10). There is evidence of further genetic heterogeneity: some clinically typical patients from consanguineous families have no MASP1/COLEC11/COLEC10 variant (26789649).
• Genetic risk factors:
• Causal variants in the three genes (Section 4).
• Consanguinity — a major risk factor; most reported families are consanguineous with homozygous variants.
• Founder alleles — e.g., COLEC10 c.311G>T (p.Gly104Val) in Ashkenazi Jews (carrier frequency ~1/99; 35943032); COLEC10 c.807_810delCTGT in Apulia, Italy (34740859).
• Modifier genes: Model-organism data suggest other complement components (MASP-2, factor B, C3) may modify skeletal severity (41774788, model organism).
• Environmental risk factors: None established. 3MC is a monogenic Mendelian disorder; no toxin, infectious, lifestyle, occupational, age or sex exposure is a known cause. (Not applicable.)
• Protective factors: No genetic or environmental protective factors described for the developmental syndrome. (Free L-fucose is protective against CL-11-mediated renal ischemia-reperfusion injury in mice — 31914693 — but this concerns adult acquired injury, not the developmental syndrome.)
• Gene–environment interactions: None documented for 3MC syndrome. (Not applicable.)

3. Phenotypes

Frequencies drawn largely from a 7-patient cohort (41703727) and case series (PMIDs 36503917, 26789649). Onset is congenital/prenatal for structural features; course is generally stable/non-progressive (malformative) with lifelong sequelae.

• Age of onset: Congenital/prenatal (structural malformations detectable prenatally — bilateral cleft lip/palate + sacral protuberance + renal anomaly; 32441374). Growth deficiency is postnatal.
• Severity: Variable (mild to severe), even within the same gene and family (29407414 describes an adult with the facial gestalt but without cleft lip/palate, intellectual disability, or short stature).
• Progression: Non-progressive/stable malformative disorder; sequelae are lifelong.
• Quality-of-life impact: Cleft repair, hearing loss, developmental delay, short stature and limb/skeletal anomalies affect feeding, speech, hearing, mobility and learning; no formal EQ-5D/SF-36 studies exist for this ultra-rare disease (not available).

4. Genetic / Molecular Information

• Causal genes (HGNC / locus / OMIM gene / product):
• MASP1 — HGNC:6901; 3q27.3; 600521; encodes MASP-1 and MASP-3 (alternative splicing). 3MC-causing variants are truncating, or missense within exon 12* encoding the MASP-3-specific C-terminal serine protease domain (29407414).
• COLEC11 — HGNC:17213; 2p25.3; 612502; encodes collectin-11 (CL-K1 / CL-11 / collectin kidney-1)*.
• COLEC10 — HGNC:2311; 8q24.12; 607620; encodes collectin-10 (CL-L1 / collectin liver-1)*.
• Representative pathogenic variants (all germline, biallelic):
• COLEC11 p.Gly204Ser — associated with undetectable serum protein (25912189, in vitro).
• COLEC10 p.Arg9Ter (c.25C>T), p.Gly77Glufs*66 (c.226delA), p.Cys176Trp (c.528C>G) — impair CL-L1 expression/secretion (28301481, in vitro).
• COLEC10 c.311G>T; p.Gly104Val — Ashkenazi Jewish founder variant (35943032).
• COLEC10 c.807_810delCTGT; p.Cys270Serfs*33 (loss of natural stop, +24 aa) — Apulian founder (34740859).
• COLEC10 c.128_129delCA; p.Thr43AsnfsTer9 — Iranian, first homozygous frameshift (34636477).
• MASP1 c.310C>T; p.Gln104Ter — nonsense (33765348).
• MASP1 homozygous ~2 kb intragenic deletion partially affecting exon 12; also exon-level deletions (PMIDs 29407414, 41703727) — may be missed by standard exome pipelines.
• Variant classification & type: Pathogenic/likely pathogenic per ACMG/AMP; predominantly loss-of-function — nonsense, frameshift, splice, intragenic/exon-level deletions, and secretion-impairing missense. Functional consequence = loss of function (protein deficiency or non-secretion). No gain-of-function or dominant-negative mechanism reported.
• Allele frequency: Causal alleles are rare/absent in gnomAD except population-specific founders (Ashkenazi COLEC10 carrier freq ≈1.01%, 35943032).
• Somatic vs germline: Exclusively germline, biallelic (autosomal recessive). No somatic/COSMIC relevance.
• Modifier genes: Complement components MASP-2, factor B, C3 modulate skeletal phenotype in mice (41774788, model organism).
• Epigenetics: No disease-specific methylation/histone signature reported (not available).
• Chromosomal abnormalities: None characteristic; the disorder is caused by single-gene point/indel/small-deletion variants (some detectable only by careful CNV analysis of WES/WGS; 29407414).

Suggested gene/GO annotations: MASP1/COLEC11/COLEC10; GO:0001867 (complement activation, lectin pathway), GO:0030246 (carbohydrate binding), GO:0005509 (calcium ion binding).

5. Environmental Information

• Environmental factors: None known. (Not applicable — Mendelian disorder.)
• Lifestyle factors: None known (not applicable).
• Infectious agents: None (not applicable). Note the biological irony that the causative genes are innate-immune anti-microbial pattern-recognition molecules, but the syndrome itself is developmental, not infectious.

6. Mechanism / Pathophysiology

Causal chain (upstream → downstream): Biallelic LOF variant in MASP1/COLEC11/COLEC10 → deficient or mis-secreted collectin (CL-K1 or CL-L1) or non-functional MASP-3 → loss of the CL-K1·MASP-3 chemoattractant guidance cue for cranial neural crest cells (cNCC) → aberrant NCC migration/differentiation → malformation of NCC-derived and midline structures (craniofacial skeleton, palate, heart outflow, genitourinary tract, vertebral/coccygeal elements) → clinical phenotype (21258343).

• Molecular pathways: Lectin pathway of complement (and its link to the alternative pathway). CL-K1/CL-L1 form Ca²⁺-dependent heteromeric collectin complexes that associate with MASP-1/2/3 (27782323). MASP-3 is the exclusive pro-factor D activator in resting blood, linking the lectin and alternative pathways (27535802: "activated MASP-3 is the exclusive pro-FD activator in resting blood, which demonstrates a fundamental link between the lectin and alternative pathways.").
• Cellular processes: Neural crest cell migration (GO:0001755) — CL-K1 acts as a directional guidance cue (21258343). Also osteoclast differentiation (GO:0030316) — CL-11 regulates osteoclastogenesis complement-dependently (41774788, model organism/in vitro).
• Protein dysfunction: LOF via impaired secretion and loss of Ca²⁺ binding in the carbohydrate-recognition domain (CRD). Disease mutations do not necessarily block folding/oligomerization in vitro, but abolish Ca²⁺ binding and secretion, producing serum protein deficiency (25912189, in vitro).
• Metabolic/biochemical: CL-K1 recognizes high-mannose oligosaccharides and L-fucose on stressed/altered self-surfaces (PMIDs 25912189, 31914693). Enzymatically, MASP-3 has low amidolytic activity relative to other C1r/C1s/MASP proteases (23861840, in vitro/structural).
• Immune involvement: The causative molecules are innate-immune complement effectors; however, 3MC patients are not primarily immunodeficient — the phenotype reflects the developmental (non-immune) moonlighting role of these proteins ("a broader functionality of the complement system than previously anticipated," 27782323).
• Tissue-damage mechanism (adult context): In acquired renal ischemia-reperfusion injury, CL-11 binds a fucosylated damage ligand on tubular epithelium and triggers complement/C5b-9 injury — mechanistically informative but distinct from the developmental syndrome (PMIDs 28663231, 31914693, model organism).
• Molecular profiling / omics / single-cell / CRISPR screens: No disease-specific transcriptomic, proteomic, metabolomic or functional-genomics screens published for 3MC (not available); mechanistic evidence is from targeted zebrafish morphants, mouse expression/knockout, and in vitro biochemistry.

Suggested ontology terms: GO:0001755 (neural crest cell migration), GO:0001867 (lectin-pathway complement activation), GO:0030316 (osteoclast differentiation), GO:0045087 (innate immune response); CL:0000333 (migratory neural crest cell / cranial NCC), CL:0000138 (chondrocyte), CL:0000092 (osteoclast); CHEBI:2181 (L-fucose), CHEBI:29108 (calcium(2+)), CHEBI:37671 (high-mannose oligosaccharide/mannose).

7. Anatomical Structures Affected

• Organ / system level:
• Craniofacial skeleton & face (UBERON:0001456 face; UBERON:0001716 secondary palate) — cleft lip/palate, hypertelorism, dysmorphism.
• Skull sutures (UBERON:0000905) — craniosynostosis.
• Eyes / periocular (UBERON:0000970) — blepharophimosis, ptosis, anterior-segment dysgenesis (UBERON:0000481 anterior chamber).
• Skeleton / limbs — radioulnar synostosis (radius UBERON:0001423 / ulna UBERON:0001424); vertebral column/coccyx (UBERON:0009832) — caudal appendage.
• Kidney & urinary tract (UBERON:0002113) — horseshoe/pelvic kidney, vesicoureteral reflux.
• Genitalia (UBERON:0000990) — genital anomalies.
• Heart (UBERON:0000948) — congenital heart disease (e.g., PDA).
• Ear / auditory system (UBERON:0001690) — hearing loss.
• CNS — developmental delay/cognitive impairment (functional).
• Tissue / cell level: Connective/skeletal tissue (cartilage, bone) and epithelial (palatal) tissue; the key targeted cell population is the cranial neural crest cell (CL:0000333) and its derivatives (chondrocytes, cranial mesenchyme); osteoclasts implicated in skeletal maintenance (41774788).
• Subcellular level: Secreted proteins traffic through the endoplasmic reticulum / secretory pathway (GO:0005783 ER; GO:0005576 extracellular region); LOF mutations cause ER retention / secretion failure (25912189).
• Localization / lateralization: Malformations are typically bilateral/midline (bilateral cleft lip/palate, hypertelorism, radioulnar synostosis often bilateral), consistent with a midline/symmetric developmental patterning defect.

8. Temporal Development

• Onset: Congenital — structural anomalies arise during embryogenesis and are detectable prenatally (first prenatal diagnosis: bilateral cleft lip/palate + sacral abnormality + pelvic kidney + brachycephaly; 32441374). Growth deficiency is postnatal.
• Onset pattern: Non-acute; features are present from birth (insidious/static developmental).
• Progression: Non-progressive malformative syndrome; stable course. Skeletal contractures or scoliosis may require intervention over time (e.g., knee flexion contracture managed with a Taylor Spatial Frame — 34589314).
• Disease course / duration: Chronic, lifelong; individuals can survive to adulthood (29407414 describes a 21-year follow-up in an adult).
• Remission / critical periods: No remission (structural). The critical window is embryonic craniofacial neural-crest migration; interventions are corrective/supportive postnatally rather than preventive of the malformation.

9. Inheritance and Population

• Epidemiology: Ultra-rare; <50 molecularly confirmed COLEC11/MASP1 patients reported as of 2020 (32441374), with additional COLEC10 cases since. Formal prevalence/incidence per 100,000 is not established (not available).
• Inheritance: Autosomal recessive (all three genes) (PMIDs 21258343, 28301481).
• Penetrance / expressivity: Presumed high penetrance for a recognizable phenotype in biallelic carriers, but highly variable expressivity (mild adult cases lacking cleft/ID/short stature — 29407414).
• Genetic anticipation: Not applicable (no repeat expansion).
• Germline mosaicism: Not reported.
• Founder effects / consanguinity: Strong role of consanguinity; documented founders — Ashkenazi Jewish COLEC10 c.311G>T (carrier frequency 1 in 99, 35943032) and Apulian (Italian) COLEC10 c.807_810delCTGT (34740859).
• Carrier frequency: ≈1.01% in Ashkenazi Jews for the COLEC10 founder allele; otherwise very rare (35943032).
• Population demographics: Cases reported worldwide (Turkey/Kurdish, Iran, Italy, Mexico, Ashkenazi Jewish, and others), often from consanguineous or founder populations. Sex ratio: roughly equal (autosomal; cohort of 7 had 5 F / 2 M — small-sample skew, 41703727). Age distribution: predominantly diagnosed in infancy/childhood.

10. Diagnostics

• Clinical recognition: Diagnosis is suspected on the facial gestalt (hypertelorism, blepharophimosis, blepharoptosis, highly arched eyebrows) plus cleft lip/palate and — a relatively specific clue — a caudal appendage (PMIDs 34899147, 26789649).
• Genetic testing (confirmatory, gold standard):
• Whole-exome (WES) / whole-genome (WGS) sequencing or a 3MC/multiple-congenital-anomaly gene panel covering MASP1, COLEC11, COLEC10. Important caveat: some clinical exome panels omit COLEC10, causing missed diagnoses — targeted Sanger of COLEC10 may be needed (34740859).
• CNV / deletion analysis: exon-level and intragenic deletions occur (MASP1) and can be missed by routine pipelines — require careful visual/CNV analysis of WES/WGS (PMIDs 29407414, 41703727).
• Single-gene / Sanger for founder alleles (e.g., Ashkenazi COLEC10 c.311G>T).
• Karyotype/FISH/mtDNA/repeat-expansion testing: not indicated (normal/uninformative).
• Biomarkers / functional assays: Serum/plasma CL-K1 or CL-L1 levels may be reduced/undetectable with secretion-impairing variants (25912189), but levels can be normal despite pathogenic variants (34740859) — so protein level is supportive, not definitive.
• Imaging: Prenatal ultrasound (facial clefts + sacral/spinal defect + renal anomaly; 32441374); postnatal skeletal survey/radiographs (radioulnar synostosis, craniosynostosis, coccygeal appendage); renal ultrasound; echocardiography; audiology; ophthalmologic exam (anterior-segment).
• Clinical criteria / differential diagnosis: No formal consensus criteria. Differential includes other blepharophimosis–ptosis syndromes (e.g., BPES), oral-facial-clefting syndromes, Fraser syndrome, and other craniofacial-limb-renal syndromes; the caudal appendage + radioulnar synostosis + facial gestalt combination and molecular confirmation distinguish 3MC (35943032 notes 3MC should be in the differential for short stature + radioulnar synostosis + cleft lip/palate).
• Screening: Carrier / cascade screening in founder populations (Ashkenazi Jewish COLEC10) and consanguineous families; prenatal molecular testing feasible once a family variant is known (32441374). No newborn-screening program exists.

11. Outcome / Prognosis

• Survival / mortality: No formal survival statistics; the disorder is generally compatible with survival to adulthood (29407414, 21-year follow-up). Severe multi-organ involvement (cardiac, renal) can affect prognosis in individual cases.
• Morbidity / function: Chronic disability from cognitive impairment, hearing loss, short stature, cleft-related speech/feeding issues, and skeletal/limb constraints (radioulnar synostosis, contractures). Variable — some individuals have mild, near-normal cognition (29407414).
• Quality-of-life measures: No disease-specific QoL data (not available).
• Complications: Cleft-related feeding/speech difficulties and otitis/hearing loss; renal anomalies may predispose to urinary complications; skeletal contractures/scoliosis; psychiatric comorbidity reported (ADHD/ODD/depression; 37463393).
• Recovery / prognostic factors: Malformations are static; outcomes improve with corrective surgery, hearing rehabilitation, and developmental support. Prognosis is modulated by severity of cardiac/renal/CNS involvement. No validated prognostic biomarkers.

12. Treatment

No disease-modifying or gene-specific therapy exists. Management is multidisciplinary, symptomatic, and supportive.

• Pharmacotherapy: None specific to 3MC. Symptomatic (e.g., stimulants/SSRIs for comorbid ADHD/depression as clinically indicated; 37463393). No pharmacogenomic considerations established. (NCIT: Supportive Care; Symptomatic Treatment.)
• Advanced therapeutics (gene/cell/RNA/targeted/immuno): None approved or in trials for 3MC (not applicable). The lectin-pathway/CL-11 axis is a therapeutic target in acquired renal IRI (L-fucose decoy strategy, 32472330, model organism) — not for the developmental syndrome.
• Surgical / interventional: Cleft lip and palate repair (NCIT: Cleft Lip Repair / Cleft Palate Repair); craniofacial/craniosynostosis surgery; ptosis/blepharophimosis correction; orthopedic correction of limb contractures/synostosis (e.g., Taylor Spatial Frame for knee flexion contracture, 34589314); urologic/genital corrective surgery as needed.
• Supportive / rehabilitative: Hearing aids/audiologic management; speech therapy; physical/occupational therapy; growth and nutritional monitoring; developmental/educational support; ophthalmologic care.
• Treatment strategy: Individualized, coordinated by clinical genetics + craniofacial/plastic surgery, ENT/audiology, orthopedics, urology/nephrology, cardiology, ophthalmology, and developmental pediatrics. Genetic counseling is integral.
• Experimental treatments / trials: None registered specifically for 3MC (not available).

Suggested NCIT terms: Supportive Care; Surgical Procedure; Cleft Lip Repair; Cleft Palate Repair; Physical Therapy; Genetic Counseling; Hearing Aid.

13. Prevention

• Primary prevention: Not preventable once conceived (congenital genetic disorder). Preconception risk reduction via genetic counseling for consanguineous couples and known-carrier families.
• Secondary prevention / early detection: Prenatal molecular diagnosis and prenatal ultrasound (facial clefts + sacral/renal anomalies) enable early identification and reproductive planning (32441374). Preimplantation genetic testing (PGT-M) is an option when the familial variant is known.
• Genetic screening: Carrier and cascade screening — high-yield in the Ashkenazi Jewish population for COLEC10 c.311G>T (carrier ~1/99) and in consanguineous/founder populations (35943032).
• Counseling: Autosomal-recessive recurrence risk 25% per pregnancy for carrier couples; molecular confirmation "allows for alternate reproductive options" (32441374).
• Tertiary prevention: Early cleft repair, hearing rehabilitation, developmental therapy, and orthopedic/urologic surveillance to limit complications.
• Immunization / public-health / environmental interventions: Not applicable.

14. Other Species / Natural Disease

• Taxonomy of gene orthologs: MASP1, COLEC11, COLEC10 are conserved in vertebrates — Mus musculus (NCBI Taxon 10090), Danio rerio (7955), Homo sapiens (9606).
• Naturally occurring animal disease: No naturally occurring 3MC-equivalent Mendelian disease is catalogued in companion animals/livestock (OMIA — not available). Phenotypes are known only from engineered/experimental models.
• Comparative biology / conservation: The lectin complement pathway and its developmental role are evolutionarily conserved; zebrafish colec11/masp1 knockdown reproduces craniofacial and pigmentary defects (21258343), demonstrating conserved mechanism.
• Transmission / zoonosis: Not applicable (genetic, non-transmissible).

15. Model Organisms

• Zebrafish (Danio rerio, ZFIN): Morpholino knockdown (morphants) of colec11 or masp1 produce pigmentary defects and severe craniofacial abnormalities — the key model recapitulating the human craniofacial phenotype and demonstrating the neural-crest guidance mechanism (21258343, model organism). Recapitulation: strong for craniofacial/neural-crest features.
• Mouse (Mus musculus, MGI):
• Expression studies: CL-K1 is highly expressed in embryonic craniofacial cartilage, heart, bronchi, kidney, and vertebral bodies (21258343); COLEC10/CL-L1 is expressed in the base membrane of the developing palate (28301481) — spatially concordant with affected human structures.
• Knockouts: CL-11 (Colec11) knockout alone does not reproduce skeletal abnormalities; combined CL-11 + MASP-2 / factor B / C3 deficiency causes vertebral bone loss and spinal curvature via impaired osteoclastogenesis (41774788, model organism) — a limitation (single-gene mouse KO under-recapitulates the human skeletal phenotype) and a clue that complement modifiers matter.
• In vitro / cellular models: Mammalian expression systems demonstrating that disease mutations block CL-K1/CL-L1 secretion and Ca²⁺ binding (PMIDs 25912189, 28301481); human iPSC-derived osteoclasts showing CL-11 dependence (41774788); recombinant MASP-3 serine-protease domain structural/enzymatic studies (23861840).
• Model limitations: Mouse single-gene KOs incompletely reproduce the full malformation spectrum (skeletal features require compound complement deficiency); morpholino zebrafish models capture craniofacial/pigment phenotypes but are transient knockdowns.
• Resources: ZFIN (zebrafish), MGI/IMPC (mouse), Cellosaurus (iPSC lines).

Evidence Source Summary

Limitations and Future Directions

• Ultra-rarity: <~100 molecularly confirmed patients; frequencies are from small cohorts and case reports, limiting precision of penetrance/expressivity and genotype–phenotype correlation.
• Genetic heterogeneity: Some clinically typical, consanguineous patients lack variants in the three known genes (26789649) — additional lectin-pathway genes likely remain to be discovered.
• No omics datasets: No published transcriptomic/proteomic/metabolomic/single-cell profiling of patient tissues; mechanism rests on targeted models and biochemistry.
• Future directions: Deeper phenotyping registries; CNV-aware sequencing (to capture exon-level deletions); functional CL-K1/CL-L1 assays as adjunct diagnostics; delineating the neural-crest guidance mechanism at single-cell resolution; exploring complement modifiers of skeletal severity.